Edilio Borroni

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11258000/publications.pdf

Version: 2024-02-01

42 papers	3,082 citations	186265 28 h-index	243625 44 g-index
45 all docs	45 docs citations	45 times ranked	3721 citing authors

#	Article	IF	Citations
1	Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease. JAMA Neurology, 2022, 79, 149.	9.0	66
2	The impact of demographic, clinical, genetic, and imaging variables on tau PET status. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2245-2258.	6.4	27
3	Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease. JAMA Neurology, 2021, 78, 961.	9.0	148
4	Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders. JAMA Neurology, 2020, 77, 955.	9.0	136
5	Characterization of 3 Novel Tau Radiopharmaceuticals, ¹¹C-RO-963, ¹¹C-RO-643, and ¹⁸F-RO-948, in Healthy Controls and in Alzheimer Subjects. Journal of Nuclear Medicine, 2018, 59, 1869-1876.	5.0	81
6	Preclinical Evaluation of ¹⁸F-RO6958948, ¹¹C-RO6931643, and ¹¹C-RO6924963 as Novel PET Radiotracers for Imaging Tau Aggregates in Alzheimer Disease. Journal of Nuclear Medicine, 2018, 59, 675-681.	5.0	71
7	Evaluation of ¹⁸F-RO-948 PET for Quantitative Assessment of Tau Accumulation in the Human Brain. Journal of Nuclear Medicine, 2018, 59, 1877-1884.	5.0	64
8	Kinetic Modeling of the Tau PET Tracer ¹⁸F-AV-1451 in Human Healthy Volunteers and Alzheimer Disease Subjects. Journal of Nuclear Medicine, 2017, 58, 1124-1131.	5.0	60
9	Sembragiline: A Novel, Selective Monoamine Oxidase Type B Inhibitor for the Treatment of Alzheimerâ€™s Disease. Journal of Pharmacology and Experimental Therapeutics, 2017, 362, 413-423.	2.5	72
10	Identification of Three Novel Radiotracers for Imaging Aggregated Tau in Alzheimerâ€™s Disease with Positron Emission Tomography. Journal of Medicinal Chemistry, 2017, 60, 7350-7370.	6.4	74
11	[ICâ€Pâ€188]: ON EVALUATION OF TAU ACCUMULATIONS IN LONGITUDINAL STUDIES OF ALZHEIMER's DISEASE (AD): IMPLICATIONS FROM A PET STUDY WITH [18F]RO6958948. Alzheimer's and Dementia, 2017, 13, P139.	0.8	5
12	Sembragiline in Moderate Alzheimerâ€™s Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD). Journal of Alzheimer's Disease, 2017, 58, 1217-1228.	2.6	33
13	P4â€185: First inâ€human PET study of 3 novel tau radiopharmaceuticals: [¹¹C]RO6924963, [¹¹C]RO6931643, and [¹⁸F]RO6958948. Alzheimer's and Dementia, 2015, 11, P850.	0.8	12
14	Pharmacology of Basimglurant (RO4917523, RG7090), a Unique Metabotropic Glutamate Receptor 5 Negative Allosteric Modulator in Clinical Development for Depression. Journal of Pharmacology and Experimental Therapeutics, 2015, 353, 213-233.	2.5	90
15	Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators: Discovery of 2-Chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]pyridine (Basimglurant,) Tj ETQq1 1 0.784314 rgBT /Overlo 58, 1358-1371.	6.4	58
16	Application of cross-species PET imaging to assess neurotransmitter release in brain. Psychopharmacology, 2015, 232, 4129-4157.	3.1	61
17	Label-free assay for the assessment of nonspecific binding of positron emission tomography tracer candidates. European Journal of Pharmaceutical Sciences, 2015, 79, 27-35.	4.0	25
18	Effect of Bitopertin, a Glycine Reuptake Inhibitor, on Negative Symptoms of Schizophrenia. JAMA Psychiatry, 2014, 71, 637.	11.0	185

#	Article	IF	Citations
19	Characterization of [11C]RO5013853, a novel PET tracer for the glycine transporter type 1 (GlyT1) in humans. NeuroImage, 2013, 75, 282-290.	4.2	26
20	Pre-clinical characterization of [11C]R05013853 as a novel radiotracer for imaging of the glycine transporter type 1 by positron emission tomography. NeuroImage, 2013, 75, 291-300.	4.2	16
21	Glycine reuptake inhibitor RG1678: A pharmacologic characterization of an investigational agent for the treatment of schizophrenia. Neuropharmacology, 2012, 62, 1152-1161.	4.1	122
22	Dual Hypocretin Receptor Antagonism Is More Effective for Sleep Promotion than Antagonism of Either Receptor Alone. PLoS ONE, 2012, 7, e39131.	2.5	107
23	Molecular Recognition at the Active Site of Catecholâ€Oâ€methyltransferase (COMT): Adenine Replacements in Bisubstrate Inhibitors. Chemistry - A European Journal, 2011, 17, 6369-6381.	3.3	35
24	Discovery of benzoylisoindolines as a novel class of potent, selective and orally active GlyT1 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 6960-6965.	2.2	17
25	Selective GlyT1 Inhibitors: Discovery of [4-(3-Fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]metha (RG1678), a Promising Novel Medicine To Treat Schizophrenia. Journal of Medicinal Chemistry, 2010, 53, 4603-4614.	6.4	134
26	Molecular Recognition at the Active Site of Catecholâ€Oâ€Methyltransferase: Energetically Favorable Replacement of a Water Molecule Imported by a Bisubstrate Inhibitor. Angewandte Chemie - International Edition, 2009, 48, 9092-9096.	13.8	39
27	RO4938581, a novel cognitive enhancer acting at GABAA Î±5 subunit-containing receptors. Psychopharmacology, 2009, 202, 207-223.	3.1	142
28	Discovery of benzoylpiperazines as a novel class of potent and selective GlyT1 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 5134-5139.	2.2	25
29	Trace Amine-Associated Receptor 1 Modulates Dopaminergic Activity. Journal of Pharmacology and Experimental Therapeutics, 2008, 324, 948-956.	2.5	288
30	Age-dependent cognitive decline and amygdala pathology in Î±-synuclein transgenic mice. Neurobiology of Aging, 2007, 28, 1421-1435.	3.1	154
31	Bisubstrate Inhibitors of CatecholO-Methyltransferase (COMT): the Crucial Role of the Ribose Structural Unit for Inhibitor Binding Affinity. ChemMedChem, 2006, 1, 340-357.	3.2	29
32	Synthesis and Biological Evaluation of Potent Bisubstrate Inhibitors of the Enzyme CatecholO-Methyltransferase (COMT) Lacking a Nitro Group. Helvetica Chimica Acta, 2006, 89, 1856-1887.	1.6	16
33	Bisubstrate Inhibitors of the Enzyme Catechol O-Methyltransferase (COMT): Efficient Inhibition Despite the Lack of a Nitro Group. ChemBioChem, 2004, 5, 1270-1274.	2.6	29
34	Bisubstrate Inhibitors for the Enzyme Catechol O-Methyltransferase (COMT): Dramatic Effects of Ribose Modifications on Binding Affinity and Binding Mode. Helvetica Chimica Acta, 2003, 86, 1045-1062.	1.6	18
35	Bisubstrate inhibitors for the enzyme catechol-O-methyltransferase (COMT): influence of inhibitor preorganisation and linker length between the two substrate moieties on binding affinity. Organic and Biomolecular Chemistry, 2003, 1, 42-49.	2.8	52
36	Misfolded proteinase Kâ€“resistant hyperphosphorylated Î±-synuclein in aged transgenic mice with locomotor deterioration and in human Î±-synucleinopathies. Journal of Clinical Investigation, 2002, 110, 1429-1439.	8.2	292

#	Article	IF	Citations
37	X-ray Crystal Structure of a Bisubstrate Inhibitor Bound to the Enzyme Catechol-O-methyltransferase: A Dramatic Effect of Inhibitor Preorganization on Binding Affinity We thank F. Hoffmannâ€“La Roche for generous support of this work. We are grateful to P. Malherbe for the cloning of COMT, P. Caspers for the expression of COMT, A. Cesura for enzyme purification, B. Wipf for fermentation, and H. W. Lahm for sequencing.. Angewandte Chemie - International Edition, 2001, 40, 4040.	13.8	62
38	Structure-Based Design, Synthesis, and in vitro Evaluation of Bisubstrate Inhibitors for CatecholO-Methyltransferase (COMT). Chemistry - A European Journal, 2000, 6, 971-982.	3.3	65
39	The developmental expression of the cholinergic-specific antigen Chol-1 in the central and peripheral nervous system of the rat. Developmental Brain Research, 1990, 52, 131-140.	1.7	24
40	Further studies on the gangliosidic nature of the cholinergic-specific antigen, Chol-1. Archives of Biochemistry and Biophysics, 1990, 280, 211-216.	3.0	16
41	Cholinergic Surface Antigen Chol-1 Is Present in a Subclass of VIP-Containing Rat Cortical Synaptosomes. Journal of Neurochemistry, 1988, 50, 1659-1662.	3.9	26
42	Putative Cholinergicâ€Specific Gangliosides in Guinea Pig Forebrain. Journal of Neurochemistry, 1986, 46, 1888-1894.	3.9	35